Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.

Marketing 52

Marketing Physicians Leads Competition 52

Pharmaceutical Technology

JULY 8, 2022

Blincyto has provided a strong positive signal to demonstrate the clinical and commercial viability of BiTEs, with 2021 company-reported global sales of $542 million and GlobalData’s analyst consensus forecast projecting peak annual sales of $771 million by 2029, thereby sparking further industry interest in this field. months vs. 4.0

Safety 59

Safety Sales Marketing Patients 59

European Pharmaceutical Review

OCTOBER 26, 2023

Yet as the market continues to recognise the value of these treatments, especially with them having “clear benefits over current monotherapy and combination therapy options in cancer treatment”, it is unsurprising that GlobalData’s research predicted the ADC oncology therapy market will value more than $36 billion by 2029.

Patients 94

Patients Pharmaceutical Safety Marketing 94

PM360

SEPTEMBER 21, 2023

Under the pathway, manufacturers can use safety and efficacy data from existing products in their applications for their own products. This increases to 15 Part D drugs in 2026, as well as 15 Part B and D drugs in 2028, and a full 20 Part B and D drugs in 2029. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Pharmaceutical Technology

JUNE 13, 2023

As for safety, 85% had at least one Grade 3 or higher treatment-emergent adverse event (TEAE). According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

Patients 52

Patients Sales Competition Safety 52

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 102

Safety Electronics Recruitment Medical 102

Medico Reach

OCTOBER 17, 2022

billion by 2029. From procedure efficacy and cost to safety and training, there are still several challenges to overcome before robot-assisted surgery becomes standard practice. However, current orthopedic medical device trends all point towards the increasing use of such systems. There is a caveat here, though.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98